Based on the prior data, we aimed to explore if resistance to BRAFi would be reverted by targeting SRC, and proposed a novel treatment strategy for BRAFV600E CRC based on dual inhibition of SRC (dasatinib) and BRAF (vemurafenib or encorafenib). Here, BRAF is linked to colorectal carcinoma.